Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout within ...

Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets ...

TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease ...

The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure with a ...

FDA aligns on RP-A501 Phase 2 trial design for Danon disease, approving a 12-patient pivotal population and 12-month endpoint structure.

Mednet AI intake tool automates EHR-to-EDC data entry in clinical trials, reducing manual transcription and entry errors for research coordinators.

Hinge Bio runs its Phase I trial on a single Medrio platform, consolidating EDC, ePRO, and RTSM to reduce setup time and site burden.

Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT ...

FDA held public hearing on psychedelic drug therapy with 80 speakers. Explore debates on safety, credentialing, and equitable ...

CRB-913 obesity drug achieved 5% weight loss in Phase 1b trial, signaling potential for a peripheral CB1 mechanism without central nervous system effects.

Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without ...

Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...